
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

# Stem Cells The Holy Grail

14 October 2008 | News



Stem Cells

# The Holy Grail

*Patients across the world are holding on to the tenuous thread of life by the hope stem cell therapy provides while the research itself is facing challenges of all kinds-scientific, political, legal and ethical. In this special report BioSpectrum captures what the business leaders are doing to commercialize the research and sustain until we reach the goa*lpost.

**Penetration of Stem Cell Therapy in APAC Region**

- Singapore has the highest penetration for stem cell therapy, achieving almost 25% penetration rate by 2010.
- Both Thailand & Taiwan have similar penetration rates achieving overall penetration of almost 4% by 2010.
- Malaysia on the other hand has a relatively lower penetration rate at 1.2% by 2010.
- India offers penetration of 5% by 2010 largely accounted by stem cell therapies derived out of cord blood banking. It has
  three international players already creating a headstart.
- In the APAC regions, Singapore has the highest penetration with a CAGR of almost 66% for market penetration over the next five years. Malaysia leads second with a CAGR of 33%. Taiwan & Thailand lead on the basis of sheer numbers, but would have a comparatively lower demand trajectory due to restrictive healthcare policies. Source: Stempeutics

Narayan Kulkarni & Sanjeev Jain